<DOC>
	<DOCNO>NCT02682121</DOCNO>
	<brief_summary>Diabetes mellitus ( DM ) impose approximate 2-fold increase risk atherothrombosis . Patients type 2 DM 2- 4-fold increase risk coronary artery disease ( CAD ) atherothrombotic complication . Current evidence indicates alter platelet function `` reactivity '' key determinant arterial venous thrombosis metabolic syndrome . In addition , venous thrombosis pulmonary embolism associate increase body mass index , common feature type 2 DM metabolic syndrome . Altered platelet behavior , function , phenotype may critical factor thrombotic complication well . The mechanisms lead alter phenotype function platelet DM , underlie heighten contribution platelet thrombotic complication type 2 DM , nevertheless incompletely understood . In project , investigator prospectively determine clinical intervention metformin -- commonly-used therapeutic agent reduces blood glucose , promotes weight loss , improve lipid profile -- reverse platelet reprogramming hyperreactivity obese subject impair fast glucose thus , at-risk type 2 DM . In addition metformin , participant give lifestyle modification ( LSM ) education diet physical activity , follow guidance adhere LSM , depend random assignment intervention group ( education ( n=26 ) vs. implementation intention alone ( n=27 ) vs. implementation intention partner ( n=27 ) ) . The LSM coach different intervention group allow investigator test whether effective way adherence others . Participants three LSM intervention group randomize either Metformin ( n=40 ) Placebo ( n=40 ) , participant three LSM group randomly evenly distribute across two study medication group .</brief_summary>
	<brief_title>Mitochondrial-related Platelet Transcript Expression Levels Pre-diabetic Subjects Randomized Metformin Placebo</brief_title>
	<detailed_description />
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>ageâ‰¥18 year BMI &gt; 25 kg/m2 fast plasma glucose 100125 mg/dL , AND/OR HemoglobinA1C 5.5 6.4 % , AND/OR postload glucose 140 199 mg/dL 2hour Oral Glucose Tolerance Test ( OGTT ) All inclusion criterion check participant ' first inperson visit . unwilling accept treatment assignment randomization participation another clinical research trial history myocardial infarction stroke significant arrhythmia ( e.g . atrial fibrillation ) active thromboembolic disease inflammatory bowel disease serum creatinine level great equal 1.5 mg/dL male great equal 1.4 mg/dL female know hypersensitivity metformin hydrochloride component acute chronic metabolic acidosis inability participate lifestyle modification pregnancy ; glucoselowering diabetic therapy systemic glucocorticoid prescription weight loss medication otherwise deem unsuitable study investigator ( e.g . unable complete followup visit , alcohol abuse , etc ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>